Dynamic light scattering (DLS) spectroscopy measures the Brownian movement of particles. Fifteen patients underwent DLS measurement and positron emission tomography amyloid imaging. The DLS measurement is noninvasive, quantitative, and inexpensive, with immediate results. We report a significant correlation between DLS measurements and Centiloid values.
MontineTJPhelpsCHBeachTG, et al.National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol2012; 123: 1–11.
3.
RabinoviciGDKnopmanDSArbizuJ, et al.Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement2025; 21: e14338.
4.
DumbaMKhanSPatelN, et al.Clinical 18F-FDG and amyloid brain positron emission tomography/CT in the investigation of cognitive impairment: where are we now?Br J Radiol2019; 92: 20181027.
5.
CollijLEBollackALa JoieR, et al.Centiloid recommendations for clinical context-of-use from the AMYPAD consortium. Alzheimers Dement2024; 20: 9037–9048.
6.
CoathWModatMCardosoMJ, et al.Operationalizing the centiloid scale for [18F]florbetapir PET studies on PET/MRI. Alzheimers Dement (Amst)2023; 15: e12434.
7.
IaccarinoLBurnhamSCTunaliI, et al.A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research. Neuroimage Clin2025; 46: 103765.
8.
BourgeatPDoréVRoweCC, et al.A universal neocortical mask for Centiloid quantification. Alzheimers Dement (Amst)2023; 15: e12457.
9.
SalvadóGMolinuevoJLBrugulat-SerratA, et al.Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther2019; 11: 27.
10.
BourgeatPDoréVDoeckeJ, et al.Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies. Neuroimage2021; 226: 117593.
11.
KwonHSKimJYKohSH, et al.Predicting cognitive stage transition using p-tau181, Centiloid, and other measures. Alzheimers Dement2023; 19: 4641–4650.
12.
PembertonHGCollijLEHeemanF, et al.Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging2022; 49: 3508–3528.
13.
FarrarGWeberCJRabinoviciGD. Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable. J Prev Alzheimers Dis2025; 12: 100008.
14.
HanseeuwBJMalotauxVDricotL, et al.Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging2021; 48: 302–310.
15.
DiFilippoFPRaoSM. Evaluation of two clinical Centiloid analysis products for 18F-florbetapir PET in cognitively unimpaired elders. Alzheimers Dement (Amst)2025; 17: e70163.
16.
ShekariMVállez GarcíaD, et al.Stress testing the Centiloid: precision and variability of PET quantification of amyloid pathology. Alzheimers Dement2024; 20: 5102–5113.
17.
YamaoTMiwaKKanekoY, et al.Deep learning-driven estimation of Centiloid scales from amyloid PET images with 11C-PiB and 18F-labeled tracers in Alzheimer's disease. Brain Sci2024; 14: 406.
18.
WeissJN. Dynamic light scattering of the eye in the diagnosis of Alzheimer’s disease. J Alzheimers Dis2025; 103: 349–352.
19.
WeissJN. Dynamic light-scattering method could guide Alzheimer’s diagnosis and treatment. BioPhotonics2023; 30: 46–49.
20.
WeissJNEberD. Earlier diagnosis of Alzheimer’s disease by dynamic light scattering spectroscopy. J Alzheimers Dis2025; 104: 649–652.
21.
WeissJN. Dynamic light scattering spectroscopy of the human eye. Springer, 2022.
22.
DavisMRRobinsonEKoronyoY, et al.Retinal ganglion cell vulnerability to pathogenic tau in Alzheimer’s disease. Acta Neuropathol Commun2025; 13: 31.
23.
StoneM. Cross-validatory choice and assessment of statistical predictions. J R Stat Soc Series B Methodol1974; 36: 111–147.
24.
RasmussenJLangermanH. Alzheimer’s disease - why we need early diagnosis. Degener Neurol Neuromuscul Dis2019; 9: 123–130.
25.
van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2023; 388: 9–21.
26.
CummingsJApostolovaLRabinoviciGD, et al.Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis2023; 10: 362–377.
27.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
28.
PontecorvoMJMintunMA. PET Amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer’s disease. Alzheimers Res Ther2011; 3: 11.
29.
AraiH. Underestimated Centiloid values in amyloid PET: a technical report on clinically relevant quantification errors. Cureus2025; 17: e97398.
30.
YoonYJSeoSLeeS, et al.Centiloid values from deep learning-based CT parcellation: a valid alternative to freesurfer. Alzheimers Res Ther2025; 17: 212.
31.
KlunkWEKoeppeRAPriceJC, et al.The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement2015; 11: 1–15.e1-4.
